Grifols (GIKLY) Cash & Equivalents (2009 - 2025)
Grifols (GIKLY) posted Cash & Equivalents of $923.1 million for Q4 2025, down 11.85% quarter-over-quarter from $1.0 billion in Q4 2024, and down 11.85% year-on-year from $1.0 billion in Q4 2024.
Grifols (GIKLY) Cash & Equivalents (2009 - 2025) Analysis & Trends
Grifols (GIKLY) has reported Cash & Equivalents for 16 consecutive years, with $923.1 million the latest figure, recorded in Q4 2025.
- Cash & Equivalents for Q4 2025 came in at $923.1 million, down 11.85% year-over-year; the trailing twelve-month figure through Dec 2025 was $923.1 million (down 11.85% YoY), and the FY2025 annual result was $923.1 million, down 11.85% from the prior year.
- Cash & Equivalents was $923.1 million for Q4 2025 at Grifols, down from $1.0 billion in the prior quarter.
- Over five years, Cash & Equivalents peaked at $3.1 billion in Q4 2021 and troughed at $560.1 million in Q4 2022.
- Average Cash & Equivalents over 5 years is $1.2 billion, with a median of $923.1 million recorded in 2025.
- Year-over-year, Cash & Equivalents surged 342.97% in 2021 and slumped 81.7% in 2022.
- Over 5 years, Cash & Equivalents stood at $3.1 billion in 2021, then plunged by 81.7% to $560.1 million in 2022, then gained by 1.62% to $569.2 million in 2023, then soared by 83.99% to $1.0 billion in 2024, then dropped by 11.85% to $923.1 million in 2025.
- Per Business Quant data, the three most recent Cash & Equivalents figures were $923.1 million in Q4 2025, $1.0 billion in Q4 2024, and $569.2 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 21.69 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 9.39 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 7.56 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 5.33 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 7.63 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 1.70 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | 923.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 923.09 Mn |
| Dec 31, 2024 | 1.05 Bn |
| Dec 31, 2023 | 569.17 Mn |
| Dec 31, 2022 | 560.12 Mn |
| Dec 31, 2021 | 3.06 Bn |
| Dec 31, 2020 | 691.11 Mn |
| Sep 30, 2020 | 1.21 Bn |
| Mar 31, 2020 | 703.98 Mn |
| Dec 31, 2019 | 821.29 Mn |
| Sep 30, 2019 | 881.43 Mn |
| Mar 31, 2019 | 655.51 Mn |
| Dec 31, 2018 | 1.18 Bn |
| Sep 30, 2018 | 676.95 Mn |
| Jun 30, 2018 | 797.82 Mn |
| Mar 31, 2018 | 1.04 Bn |
| Dec 31, 2017 | 1.04 Bn |
| Jun 30, 2017 | 824.90 Mn |
| Dec 31, 2016 | 966.36 Mn |
| Sep 30, 2016 | 1.01 Bn |
| Jun 30, 2016 | 911.83 Mn |